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Abstract
Objectives
Disease progression varies among HIV-1-infected individuals. The present study aimed to
explore possible viral and host factors affecting disease progression in HIV-1-infected
children.
Methods
Since 2000, 102 HIV-1 vertically-infected children have been followed-up in Kenya. Here
we studied 29 children (15 male/14 female) who started antiretroviral treatment at <5 years
of age (rapid progressors; RP), and 32 (17 male/15 female) who started at >10 years of age
(slow progressors; SP). Sequence variations in the HIV-1 gag and nef genes and the HLA
class I-related epitopes were compared between the two groups.
Results
Based on nef sequences, HIV-1 subtypes A1/D were detected in 62.5%/12.5% of RP and
66.7%/20% of SP, with no significant difference in subtype distribution between groups (p =
0.8). In the ten Nef functional domains, only the PxxP3 region showed significantly greater
variation in RP (33.3%) than SP (7.7%, p = 0.048). Gag sequences did not significantly dif-
fer between groups. The reportedly protective HLA-A alleles, A*74:01, A*32:01 and A*26,
were more commonly observed in SP (50.0%) than RP (11.1%, p = 0.010), whereas the
reportedly disease-susceptible HLA-B*45:01 was more common in RP (33.3%) than SP
(7.4%, p = 0.045). Compared to RP, SP showed a significantly higher median number of
predicted HLA-B-related 12-mer epitopes in Nef (3 vs. 2, p = 0.037), HLA-B-related 11-
mer epitopes in Gag (2 vs. 1, p = 0.029), and HLA-A-related 9-mer epitopes in Gag (4 vs. 1,
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p = 0.051). SP also had fewer HLA-C-related epitopes in Nef (median 4 vs. 5, p = 0.046)
and HLA-C-related 11-mer epitopes in Gag (median 1 vs. 1.5, p = 0.044) than RP.
Conclusions
Compared to rapid progressors, slow progressors had more protective HLA-A alleles and
more HLA-B-related epitopes in both the Nef and Gag proteins. These results suggest that
the host factor HLA plays a stronger role in disease progression than the Nef and Gag
sequence variations in HIV-1-infected Kenyan children.
Introduction
Following HIV-1 infection, the disease progression rate varies among individuals. It typically
takes about 8–10 years to progress from HIV-1 infection to AIDS development; however,
some individuals described as “rapid progressors” develop symptoms within the first 3–5 years
post-infection. Other individuals, termed “slow progressors” or “long-term non-progressors”
(LTNP) remain asymptomatic for over 10 years without anti-retroviral treatment (ART) [1, 2].
Compared to adults, children infected with HIV-1 generally progress to AIDS faster, with chil-
dren in sub-Saharan Africa progressing faster than those in developed countries [3, 4]. How-
ever, in some cases, children have remained asymptomatic through childhood into adolescence
without treatment [5, 6]. Several host and viral factors reportedly play roles in disease progres-
sion [1, 7, 8], but such findings remain inconclusive especially in the pediatric population.
Genetic analyses have shown that some LTNP are infected with attenuated strains of HIV-1
that harbor mutations—ranging from single-nucleotide polymorphisms (SNPs) to large dele-
tions—in HIV-1 structural, regulatory, and accessory genes, such as gag and nef [9]. Individuals
infected with defective nef strains have shown slower disease progression [9, 10, 11]. Similarly,
in the gag gene, some polymorphisms have been reported to be associated with disease progres-
sion [12, 13]. However, a few studies in LTNP or “elite controllers” showed no gross genetic
defects or common amino acid changes in most of the HIV-1 coding genes [14, 15]. Thus, it
remains to be verified whether mutations in the nef and gag genes play an important role in dis-
ease progression, and how this association is influenced by other viral and host factors. Cyto-
toxic T lymphocytes (CTLs) directed against Gag reportedly correlate with improved clinical
markers of disease progression [16–18], thus, supporting possible associations between both
viral and host factors in disease progression.
Host factors implicated in disease progression include chemokine receptors (e.g., CCR5)
[19], human leukocyte antigen (HLA) alleles, and single nucleotide polymorphisms [20–22].
Some HLA alleles (e.g., A74:01 and B42:01) are associated with slower disease progression,
whereas other HLA alleles (e.g., B53:01 and B45:01) are associated with accelerated progres-
sion to AIDS [20, 23]. However, the distributions and the effects of these HLA alleles vary
among different populations [20, 24, 25]. Each HLA class I molecule binds a unique set of pep-
tides, and thus has the ability to present a discrete set of antigenic peptides. Therefore, the HLA
class I genotype dictates the repertoire of CTL responses that an individual is able to mount,
which translates into different abilities to respond to an HIV infection [26, 27].
In Kenya, we have longitudinally followed-up HIV-1 vertically infected children since the
year 2000—including quarterly monitoring of CD4+ T-cell counts and biannual monitoring of
plasma viral load. We have identified rapid and slow progressors among them and reported
the HIV-1 co-receptor switch in these two groups [28]. In the present study, to elucidate the
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factors related to disease progression, we compared sequence variations in the HIV-1 gag and
nef genes between the rapid and slow progressors. We further investigated the presence of
reported protective or disease-susceptible HLA types and the predicted HLA class I binding
capability of the Gag and Nef epitopes between the two groups.
Methods
Study subjects
A population of HIV-1 vertically-infected children residing in Nyumbani children’s home in
Nairobi, Kenya, has been followed up since 2000 [28–30]. This group included 102 children
whose clinical and laboratory records were available and plasma and buffy coat samples were
stored. These children were classified into four groups: (1) rapid progressors, who started ART
prior to 5 years of age with CD4+T-cell counts of<500 cells/μl or clinical events (n = 29); (2)
medium/normal progressors, who started ART at 5–9 years of age (n = 41); (3) slow progres-
sors, who started ART at10 years of age with CD4+ T-cell counts of>200 cells/μl (n = 23);
and (4) LTNPs, who started ART or who did not yet need ART at15 years of age (n = 9). The
present study included only two groups (Table 1): the rapid progressors (as described above)
and the slow progressors and LTNPs who were considered as a single group termed “slow pro-
gressors” (n = 32). The characteristics of the two groups at sampling are shown in Table 1.
Among them 25 (86.2%) rapid progressors and 9 (28.1%) slow progressors were on ART. The
earliest-available stored plasma samples, regardless of the treatment status, were used, with
Table 1. Characteristics of the subjects.
Characteristics Rapid (N = 29) Slow (N = 32) p value
Gender Male:Female 15:14 17:15
At sampling Age (years) 4.6 (0.9–12.8) 12.5 (7.7–26.1)
VL (Log10 copies/ml) 4.7 (2.6–5.7) 4.5 (2.6–5.6)
CD4 (cells/μl) 844 (6–2000) 530 (165–1202)
Number on ART (%) 25 (86.2%) 9 (28.1%)
*ART duration (years) 1.8 (0.1–8.0) 2.3 (0.2–8.3)
HIV subtypes by Nef n = 24 n = 30 0.795
A1 15 (62.5%) 20 (66.7%) 0.752
D 3 (12.5%) 6 (20%) 0.715
C 0 3 (10%) 0.245
G 1 (4.2%) 0 0.444
CRF02 1 (4.2%) 0 0.444
CRF10 1 (4.2%) 0 0.444
D-A1 3 (12.5%) 1 (3.3%) 0.312
HIV subtypes by Gag n = 21 n = 29 0.873
A1 16 (76.2%) 20 (69.0%) 0.572
D 2 (9.5%) 4 (13.8%) 1
C 0 4 (13.8%) 0.129
G 1 (4.8%) 0 0.420
CRF02 1 (4.8%) 0 0.420
D-A1 1 (4.8%) 1 (3.4%) 1
Values: median (range); VL: HIV viral load; P values: by Chi- square test or Fisher’s exact test
*ART duration: only for children on ART
doi:10.1371/journal.pone.0137140.t001
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sample collection dates ranging from 2000 to 2011. The number of the subjects included in
each analysis varied depending on data availability, as shown in Table 2 and S1 Table.
This study proposal was approved by the ethical committees of Kenya Medical Research
Institute (SSC No. 780 and 2340), Kenya, and Kanazawa University (No. 122), Japan. A written
informed consent was obtained from the caretaker board of the children’s home.
Analyses of HIV-1 nef and gag genes
Viral RNA was extracted from 100-μl plasma samples using the SMITEST EX-R&D nucleotide
extraction kit (Genome Science Laboratories, Fukushima, Japan) following the manufacturer’s
instructions. One-step RT-PCR was performed with region-specific primers using the Super-
Script III One-step RT-PCR system with Platinum Taq DNA polymerase (Invitrogen, Carls-
bad, CA). For nested PCR, KOD FX (Toyobo, Osaka, Japan) was used to amplify the HIV-1 nef
gene, and PrimeSTAR HS DNA polymerase (Takara, Shiga, Japan) for the HIV-1 gag gene.
The nef gene was amplified using two outer primers, Nef5-1e F1 (GTGCCTCTTCAGCTA
CCACCG; 8513–8533, nucleotide positions according to HXB2) and Nef3-3e R1 (AGCATCT
GAGGGTTAGCCACT; 9488–9508), and two inner primers, Nef5-1e F2 (TGGACAGAYAG
GGTTATAGAA; 8698–8717) and Nef3-7e R2 (CACCTCCCCTGGAAAGTCCCC; 9448–
9468) [31]. The gag gene was amplified using two outer primers, MSF12B F1 (AAATCTCTA
GCAGTGGC- GCCCGAACAG; 622–649) and BJPOL3 R1 (GTTGACAGGTGTAGGTCCT
AC; 2481–2501), and two inner primers, NewGagfw2 F2 (TCTCTCGACGCAGGACT-
CGGCTT; 682–704) and SP3AS R2 (CCTCCAATTCCCCCTATCATTTTTGG; 2382–2407)
[32].
RT-PCR conditions were as follows: 30 min at 55°C and 2 min at 94°C; then 40 cycles of 20
sec at 94°C, 30 sec at 52°C for the nef gene or 58°C for the gag gene, and 1 min at 68°C; and a
final extension of 5 min at 68°C. The nested PCR conditions for the nef gene were as follows:
one cycle at 94°C for 2 min; followed by 40 cycles of 98°C for 10 sec, 53°C for 30 sec, and 68°C
for 1 min; with a final extension at 68°C for 5 min. Nested PCR conditions for the gag gene
included 98°C for 2 min; and then 40 cycles of 98°C for 10 sec, 58°C for 30 sec, and 72°C for
1 min; followed by a final extension at 72°C for 5 min. The amplified products were detected
by agarose gel electrophoresis with ethidium bromide staining. Next, direct sequencing of the
Table 2. The number of cases in each analysis.
Items Rapid (N = 29) Slow (N = 32)
Sequences available nef 24 30
gag 21 29
Variation analysis Nef 18 26
Gag 18 24
HLA class I genotype HLA-A 18 28
available HLA-B 18 27
HLA-C 13 23
Epitope analysis Nef HLA-A 16 26
HLA-B 16 25
HLA-C 13 21
Gag HLA-A 14 25
HLA-B 14 24
HLA-C 12 20
Variation analysis: only HIV-1 subtype A1 and D were included. Epitope analysis: only cases with both HLA class I genotype and Nef or Gag sequences
doi:10.1371/journal.pone.0137140.t002
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amplified products of the nef and gag regions was performed using Big Dye Terminator v1.1
on the ABI PRISM 3130 Genetic Analyzer, or the 3500XL sequencer (Applied Biosystems). A
few amplified samples could not be directly sequenced and were instead subjected to clonal
sequencing using the TOPO TA kit (Invitrogen) [29].
The generated sequences were edited using GENETYX software Ver.9 (GENETYX Corpo-
ration, Japan), and HIV subtype was determined using the NCBI genotyping tool (http://www.
ncbi.nlm.nih.gov/projects/genotyping/formpage.cgi). The sequences were aligned and trans-
lated to amino acids using Mega 5.0 software (http://www.megasoftware.net/index.php). We
screened for amino-acid variations in the already defined Nef [33] and Gag [34] functional
domains, and for deletions and insertions perturbing the open reading frames, and we com-
pared these anomalies between the rapid and slow progressors. To align the HIV-1 subtype A1
sequences, we used the reference sequence AF457052 for Nef and AF004885 for Gag. For sub-
type D, U88824 was used for both proteins.
The GenBank accession numbers for these sequences are KR020056-KR020159.
HLA class I typing
Genomic DNA was extracted from the children’s buffy coat samples using the QIAamp DNA
Blood Mini Kit (QIAGEN Sciences, MD, USA) following the manufacturer’s instructions.
HLA-A,-B, and-C genotypes were determined using the Luminex assay system and HLA typ-
ing kits (WakFlow HLA Typing kits, Wakunaga, Hiroshima, Japan) at the Kyoto HLA Labora-
tory, Kyoto Japan. The protective and disease-susceptible HLA class I alleles were defined
according to previous reports [20, 23].
HLA class I epitope prediction
The obtained Nef and Gag amino-acid sequences were used to assess the number of predicted
epitopes recognized by the HLA-A,-B, and-C alleles via an in silico method using the Immune
Epitope Database (IEDB) MHC (Major histocompatibility complex) Binding prediction tool
(http://tools.immuneepitope.org/main/html/tcell_tools.html). For the HLA-binding epitope
prediction, we selected all lengths in the IEDB (8–14 amino acids). Only high-affinity binding
peptides (IEDB percentile rank 0.5) were considered as epitopes. The number of epitopes
recognized by each subject was calculated by summing all of the epitopes recognized by all of
the HLA alleles, only counting once any epitope fragment shared by multiple HLA molecules
[27].
Statistical analysis
The Chi-square test or Fisher’s exact probability test was used to compare the HIV subtype dis-
tribution, the amino-acid differences in the Nef and Gag sequences, and the HLA distribution
between the rapid and slow progressors. The Mann-Whitney U test was used to compare the
predicted HLA-binding epitopes. All analyses were performed using the SPSS programs (IBM
SPSS statistics 19). A p value of<0.05 was considered to be statistically significant.
Results
HIV-1 subtype distributions
HIV-1 subtypes were analyzed based on the nef and gag gene sequences (Table 1 and S1
Table). The most prevalent HIV-1 subtype among rapid and slow progressors was subtype A1
(15/24, 62.5% and 20/30, 66.7% based on nef, and 16/21, 76.2% and 20/29, 69.0% based on
gag), followed by subtype D (3/24, 12.5% and 6/30, 20.0% based on nef, and 2/21, 9.5% and
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4/29, 13.8% based on gag). Subtype C was detected only in the slow progressors (3/30, 10%
based on nef and 4/29, 13.8% based on gag). Subtype distribution did not significantly differ
between the rapid and slow progressors (p = 0.795 for nef and p = 0.873 for gag). Several sam-
ples showed discordant subtypes between gag and nef genes, consisting of mainly subtypes A1
and D.
Variations in the Nef and Gag proteins
We successfully obtained HIV-1 nef gene sequences for 54 children [24 rapid progressors (RP)
and 30 slow progressors (SP)] and HIV-1 gag gene sequences for 50 children (21 RP and 29
SP) (Table 2). To determine the frequency of HIV-1 strains with amino acid substitutions in
the Nef functional domains, and to evaluate their association with disease progression rates, we
analyzed the Nef amino-acid sequences from 18 rapid progressors (15 with HIV-1 subtype A1
and 3 with subtype D) and 26 slow progressors (20 with subtype A1 and 6 with subtype D)
comparing with the subtype-specific references (Tables 1 and 2).
Analysis of the ten Nef functional domains revealed no significant differences in the total
number of amino-acid substitutions per child between the rapid progressors (median, 5; range,
2–10) and slow progressors (median, 5; range, 2–11) (p = 1). In the PxxP369–76 (SH3 binding)
region, amino-acid substitutions were more common among rapid progressors (6/18, 33.3%)
than the slow progressors (2/26, 7.7%) (p = 0.048) (S2 Table). In particular, R71K/M/T was
present in five (27.8%) rapid progressors (3K, 1M, and 1T) but in none of the slow progressors
(p = 0.008). Within the acidic cluster region EEEE62–65, the amino-acid substitutions E64D/G
were more common among slow progressors (5/26, 19.2%) than rapid progressors (0%),
though this difference was not significant (p = 0.068) (Fig 1). Both groups exhibited amino-
acid insertions and deletions, with the most common insertions being at amino-acid positions
23 and 24. No large deletions were detected. We observed no significant between-group differ-
ences regarding the number of sequences with amino acid insertions (11/18, 61.1% of RP vs.
17/26, 65.4% of SP, p = 1) and deletions (1/18, 5.6% of RP vs. 5/26, 19.2% of SP, p = 0.375).
Analysis of the 19 Gag functional domains revealed no significant differences in the total
number of amino-acid substitutions per functional domain between the rapid and slow pro-
gressors (all p>0.1, Table 3). We observed no significant between-group differences in the pro-
portion of sequences with amino-acid insertions (5/18, 27.8% of RP vs. 13/24, 54.2% of SP,
p = 0.120) and deletions (10/18, 55.6% of RP vs. 12/24, 50% of SP, p = 0.718).
Distribution of HLA class I alleles
HLA class I genotype was successfully analyzed in 46 of the 61 children, including 18 rapid
progressors and 28 slow progressors. We identified 92 HLA-A alleles (36 in RP, 56 in SP),
90 HLA-B alleles (36 in RP, 54 in SP), and 72 HLA-C alleles (26 in RP, 46 in SP) (Table 4 and
Table 2). The most commonly detected HLA-A alleles were A02:01 (11/92, 12.0%) and
A74:01 (11/92, 12.0%), followed by A68:02 (9/92, 9.8%). The most common HLA-B allele
was B53:01 (12/90, 13.3%), followed by B15:03 (11/90, 12.2%) and B42:01 (8/90, 8.9%). The
most common HLA-C allele was Cw07:01 (11/72, 15.3%), followed by Cw04:01/07 (10/72,
13.9%) and Cw02:02 (9/72, 12.5%).
The previously reported HLA-A protective alleles A74:01, A32:01 and A26 were more
commonly found among slow progressors (14/28, 50.0%) than rapid progressors (2/18, 11.1%)
(p = 0.010). HLA-A74:01 was identified in 32.1% (9/28) of slow progressors compared to
5.6% (1/18; this subject is homozygous) of rapid progressors (p = 0.064). The proportion of the
children with protective HLA-B alleles (e.g., B58:01 and B42:01) and disease-susceptible
HLA-B alleles (e.g., B53:01 and B45:01) did not significantly differ between the RP and
Factors Related to Disease Progression in HIV-1-Infected Children
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SP: protective, 50.0% (9/18) vs. 33.3% (9/27), p = 0.35; disease-susceptible, 72.2% (13/18) vs.
63.0% (17/27), p = 0.75. However, HLA-B45:01 was more common among rapid progressors
(6/18, 33.3%) than slow progressors (2/27, 7.4%) (p = 0.045). Overall, most children had a
mixture of both protective and disease-susceptible alleles, regardless of their progression status
(S1 Table).
Predicted HLA class I-related epitopes
Using the IEDB software, we determined which epitopes in the Nef and Gag proteins were
recognized with high affinity by HLA class I in each subject. For the Nef protein (Fig 2), a median
of 4 epitopes (of 8–14 amino acids in length) were recognized by HLA-A in the slow progressors,
compared to a median of 3 in rapid progressors (p = 0.059). A median of 6 epitopes were recog-
nized by HLA-B in both rapid and slow progressors (p = 0.606). A median of 5 HLA-C-related
epitopes were found in rapid progressors, compared to a median of 4 in slow progressors
(p = 0.046). Regarding epitopes of specific lengths, HLA-B-related 12-mer epitopes were more
common in the slow progressors than in the rapid progressors (median of 3 vs. 2, p = 0.037).
For the Gag protein (Fig 3), a median of 8.5 HLA-A-related epitopes (of 8–14 amino acids
in length) were found in slow progressors, compared to a median of 5.5 in rapid progressors
(p = 0.125). HLA-B-related epitopes showed no significant difference between the two groups
(median 9 vs. 9.5, p = 0.846). A median of 8 HLA-C-related epitopes were found in rapid pro-
gressors, compared to a median of 6 in slow progressors (p = 0.076). Regarding epitopes of spe-
cific lengths, the slow progressors had marginally more HLA-A-related 9-mer epitopes
(median 4 vs. 1, p = 0.051) and significantly more HLA-B-related 11-mer epitopes (median
Fig 1. Comparison of amino acid variations in Nef functional domains of HIV-1 subtypes A1 and D. The graph shows the positions (based on HIV-1
HXB2) of amino acid variations within the Nef functional domains. To compare the difference per functional domain, the presence of different amino acids
compared with the reference within that domain was considered “one”. Comparisons were performed using the Fisher’s exact test.
doi:10.1371/journal.pone.0137140.g001
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2 vs. 1, p = 0.029) than the rapid progressors. On the other hand, HLA-C-related 11-mer epi-
topes were more commonly found in rapid progressors than slow progressors (median 1.5 vs.
1, p = 0.044).
Discussion
Several viral and host factors have been described as affecting disease progression, but most
studies have investigated HIV-1-infected adults while few have examined this matter in HIV-1
vertically-infected children. In the present study, we analyzed the HIV-1 gag and nef gene
sequences and the Gag and Nef amino acid sequences from pediatric patients classified as
either rapid or slow progressors. Between these two groups, we compared the distribution of
HLA alleles and the predicted HLA class I-related epitopes to elucidate possible factors related
to disease progression.
The HIV-1 subtype distribution among the Kenyan children in this study was similar to
previous reports from studies in Kenya [35, 36]. HIV-1 subtype A1 was predominant in the
study children—representing 62.5% and 76.2% of all isolates as determined by the nef and gag
sequences, respectively—followed by subtypes D and C. Some samples showed discordant sub-
types between the nef and gag sequences, suggesting that the children were infected with
recombinant viruses. A study in Uganda described a correlation between HIV-1 subtype D
infection and rapid disease progression in adults, although HIV-1 load appeared to be the pri-
mary determinant [37]. However, our present findings indicated that subtype distribution did
not significantly differ between the rapid and slow progressors.
HIV-1 Nef has been widely studied in relation to disease progression. Large amino acid
deletions in Nef are reportedly related to slow disease progression [38], and some point
mutations in HIV-1 nef genes have been shown to be related to either slow or rapid progression
Table 3. The proportion of patients with substitutions in Gag functional domains.
Functional Domain Rapid (n = 18) Slow (n = 24) p value
% %
Basic myristoylation 22.2 12.5 0.679
Membrane binding 50 62.5 0.533
PIP2 Recognition motif 77.8 58.3 0.321
Trimer interface 1 72.2 79.2 0.720
Trimer interface 2 55.6 45.8 0.756
Nuclear localization-2 100 95.8 1
NTD-NTD Interface 1 22.2 12.5 0.679
NTD-NTD Interface 2 11.1 12.5 1
NTD-NTD Interface 3 27.8 29.2 1
Cyclophilin-A Binding 61.1 50.0 0.542
MHR (major Homology region) 50 45.8 1
Dimerization 100 83.3 0.122
Interaction domain 66.7 87.5 0.139
Zinc motif 1 33.3 25.0 0.732
Nucleocapsid basic domain 5.6 12.5 0.623
Zinc motif 2 55.6 37.5 0.525
Vpr binding 1 0 4.2 1
ALIX interaction 100 100 1
Vpr binding 2 0 4.2 1
doi:10.1371/journal.pone.0137140.t003
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Table 4. Frequency of HLA alleles in the study subjects.
A alleles (n = 92) B alleles (n = 90) C alleles (n = 72)
Number (%) Number (%) Number (%)
*02:01 11 (12.0) *53:01b 12 (13.3) *07:01 11 (15.3)
*74:01a 11 (12.0) *15:03 11 (12.2) *04:01/07 10 (13.9)
*68:02 9 (9.8) *42:01a 8 (8.9) *02:02 9 (12.5)
*23:01 8 (8.7) *45:01b 8 (8.9) *06:02 8 (11.1)
*01:01 7 (7.6) *07:02b 5 (5.6) *17:01 6 (8.3)
*29:01 6 (6.5) *49:01 5 (5.6) *16:01 5 (6.9)
*30:01 5 (5.4) *58:02b 5 (5.6) *12:03 4 (5.6)
*02:02 5 (5.4) *58:01a 4 (4.4) *04:01 3 (4.2)
*30:02 5 (5.4) *08:01b 3 (3.3) *03:02 2 (2.8)
*30:04 4 (4.3) *81:01a 3 (3.3) *06:06 2 (2.8)
*32:01a 3 (3.3) *18:01b 2 (2.2) *07:02/05 2 (2.8)
*03:01 2 (2.2) *35:01b 2 (2.2) *08:02 2 (2.8)
*24:02 2 (2.2) *44:03a 2 (2.2) *07:02/07 2 (2.8)
*26:01a 2 (2.2) *51:01/12b, 2 (2.2) *07:04 1 (1.4)
*33:01 2 (2.2) *15:10, *15:17 1 (1.1) *15:02 1 (1.4)
*34:02 2 (2.2) *35:02b, *38:01 1 (1.1) *15:03 1 (1.4)
*01:03, *02:05 1 (1.1) *39:10, *40:06 1 (1.1) *15:05 1 (1.4)
*26:12a, *29:02 1 (1.1) *41:02, *44:15 1 (1.1) *16:02 1 (1.4)
*36:01b, *66:01 1 (1.1) *57:02a, *57:03b 1 (1.1) *18:01 1 (1.4)
*11:01, *33:03 1 (1.1) *15:31, *39:01 1 (1.1)
*41:01, *50:01 1 (1.1)
*44:03/26 1 (1.1)
a: protective alleles
b: disease-susceptible alleles [20, 23].
doi:10.1371/journal.pone.0137140.t004
Fig 2. Comparison of the number of predicted HLA class I related Nef epitopes. The total number of Nef epitopes (of 8–14 amino acids in length)
recognized in silico by an individual’s HLA-A (A), HLA-B (B), and HLA-C (C), as well as the specific 12-mer length peptide recognized by HLA-B (D). Each dot
represents a result from an individual study subject. Closed circles represent rapid progressors, and open circles represent slow progressors. Horizontal lines
indicate the median number of epitopes. Statistical analyses were performed using the Mann-Whitney U test.
doi:10.1371/journal.pone.0137140.g002
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[10, 11]. Our present sequence analyses of HIV-1 strains isolated from rapid and slow
progressors demonstrated amino acid substitutions scattered throughout the whole length of
the Nef proteins, with no significant between-group differences in the amino acid deletions
and insertions. This is consistent with previous studies [14, 39, 40] in which slow progressors
did not show large deletions or extremely high numbers of deletions in the Nef protein. In the
HIV-1 Nef functional domains, the proline-rich SH3 binding domain (PxxP3) reportedly
mediates interactions between Nef and signaling molecules, such as Hck and Lyn, which are
essential for HIV-1 infectivity [41]. It is also a critical motif for MHC-I downregulation [42].
In this domain, the amino acid substitutions R71K/M/T were present in five rapid progressors
and in none of the slow progressors. This may suggest that these substitutions are related to
rapid disease progression. However, R71K, which was found in three of the five rapid progres-
sors, is also commonly found in other HIV-1 subtype A1 and D strains according to the Los
Alamos compendium (http://www.hiv.lanl.gov/content/sequence/HIV/COMPENDIUM/
2013/hiv1prot.pdf). Thus, R71K might be a normal variation of HIV-1 subtypes A1 and
Fig 3. Comparison of the number of predicted HLA class I related Gag epitopes. The total number of Gag epitopes (of 8–14 amino acids in length)
recognized in silico by an individual’s HLA-A (A), HLA-B (B), and HLA-C (C), as well as epitopes of specific lengths that showed statistically significant
differences, including 9-mer-HLA-A (D), 11-mer-HLA-B (E), and-HLA-C (F). Closed circles represent rapid progressors and open circles represent slow
progressors. Horizontal lines indicate the median number of epitopes. Statistical analyses were performed using the Mann-Whitney U test.
doi:10.1371/journal.pone.0137140.g003
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D. Additionally, all five children with R71K/M/T substitutions also had reported disease-sus-
ceptible HLA-B alleles (e.g., 08:01, 07:02, and 45:01) and did not have any reported protec-
tive HLA-A and B alleles [20]. With regard to the Gag protein, we found no significant
between-group differences in the amino acid variations, insertions, or deletions. These results
suggest that the HIV-1 Nef and Gag sequence variations are not as important as HLA in influ-
encing disease progression in Kenyan children.
Our present findings showed that the most frequent HLA class I alleles were HLA-A02:01,
B15:03, and C07:01, which is consistent with the results of previous studies in Kenya [43, 44].
This result indicated that our study group—consisting of HIV-1-infected children of different
Kenyan ethnicities—is representative of Kenyans with regard to HLA allele distribution. The
protective HLA-A alleles 74:01, 32:01 and 26 were significantly more common among the
slow progressors than the rapid progressors. This supports previous findings regarding the role
of HLA-A74:01 in slow disease progression [45–47]. On the other hand, the disease-suscepti-
ble allele HLA-B45:01 was found more commonly among rapid progressors, thus confirming
its role in rapid disease progression. These results support the hypothesis that the HLA class I
may play an important role in disease progression.
We also analyzed the HLA class I-related epitopes, which are a main factor of the interaction
between the host HLA and the virus. For both the Nef and Gag proteins, when considering all
epitopes of 8–14 amino acids in length, the slow progressors showed a tendency to recognize
more HLA-A-related epitopes. Compared to the rapid progressors, the slow progressors showed
more 9-mer predicted Gag epitopes recognized by HLA-A and 11-mer epitopes recognized by
HLA-B, and 12-mer Nef epitopes recognized by HLA-B. These results are consistent with the
findings of other in silico studies [27, 48], indicating that slow progressors recognize more epi-
topes than rapid progressors. Similarly, it has generally been observed in vitro that LTNP present
a broader CTL response, recognizing a larger set of CTL epitopes compared to progressors [49].
On the other hand, HLA-C-related epitopes were more commonly found in the rapid progres-
sors than the slow progressors, suggesting that the higher number of HLA-C-recognized epitopes
was not related to the slow progression; however, further studies are required for confirmation.
These results are consistent with previous reports that HIV-1 progression towards AIDS is
mainly determined by the HLAmolecule peptide binding capability, which is responsible for epi-
tope presentation and the possibility of mounting an efficient anti-HIV immune response [26].
The present study had several limitations, including the relatively small number of study
subjects, the different numbers of samples used for each analysis, and the fact that a majority of
the samples from the rapid progressors were collected after ART initiation. However, the 2013
WHO guidelines recommend that ART should be initiated in all HIV-infected children below
five years of age, regardless of WHO clinical stage or CD4 cell count. Thus, the present study
represents an increasingly rare opportunity to study the “rapid and slow progressors” within
this population of children.
In conclusion, our present findings showed that the slow and rapid progressors did not have
distinct sequence variations in both Nef and Gag. Compared to the rapid progressors, the slow
progressors had more protective HLA-A alleles and more HLA-B-related epitopes in both Nef
and Gag. These results suggest that the HLA, a host factor, plays a more important role in dis-
ease progression than the sequence variations in HIV-1 Nef and Gag among HIV-1-infected
Kenyan children.
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